Activity of temozolomide and bevacizumab in the treatment of locally advanced, recurrent, and metastatic hemangiopericytoma and malignant solitary fibrous tumor

Min S. Park, Shreyaskumar R. Patel, Joseph A. Ludwig, Jonathan C. Trent, Charles A. Conrad, Alexander J. Lazar, Wei Lien Wang, Piyaporn Boonsirikamchai, Haesun Choi, Xuemei Wang, Robert S. Benjamin, Dejka M. Araujo

Research output: Contribution to journalArticle

128 Scopus citations

Abstract

BACKGROUND: Hemangiopericytomas and malignant solitary fibrous tumors (HPC/SFT) are rare, closely related sarcomas with unpredictable behavior that respond infrequently to chemotherapy. An optimal systemic treatment strategy for advanced HPC/SFT has not yet been identified. METHODS: We retrospectively analyzed the records of 14 patients with histopathologically confirmed HPC/SFT who were treated at The University of Texas MD Anderson Cancer Center between May 2005 and June 2007. All patients were treated with temozolomide 150 mg/m 2 orally on days 1-7 and days 15-21 and bevacizumab 5 mg/kg intravenously on days 8 and 22, repeated at 28-day intervals. Computed tomography assessment of tumor size and density (Choi criteria) was used to determine the best response to therapy. The Kaplan-Meier method was used to estimate progression-free survival. RESULTS: The median follow-up period was 34 months. Eleven patients (79%) achieved a Choi partial response, with a median time to response of 2.5 months. Two patients (14%) had stable disease as the best response, and 1 patient (7%) had Choi progressive disease as the best response. The estimated median progression-free survival was 9.7 months, with a 6-month progression-free rate of 78.6%. The most frequently observed toxic effect was myelosuppression. CONCLUSION: Combination therapy with temozolomide and bevacizumab is a generally well-tolerated and clinically beneficial regimen for HPC/SFT patients. Additional investigation in a controlled, prospective trial is warranted.

Original languageEnglish (US)
Pages (from-to)4939-4947
Number of pages9
JournalCancer
Volume117
Issue number21
DOIs
StatePublished - Nov 1 2011

Keywords

  • anti-angiogenesis inhibitors
  • chemotherapy
  • hemangiopericytoma
  • soft tissue sarcoma
  • solitary fibrous tumors

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'Activity of temozolomide and bevacizumab in the treatment of locally advanced, recurrent, and metastatic hemangiopericytoma and malignant solitary fibrous tumor'. Together they form a unique fingerprint.

  • Cite this

    Park, M. S., Patel, S. R., Ludwig, J. A., Trent, J. C., Conrad, C. A., Lazar, A. J., Wang, W. L., Boonsirikamchai, P., Choi, H., Wang, X., Benjamin, R. S., & Araujo, D. M. (2011). Activity of temozolomide and bevacizumab in the treatment of locally advanced, recurrent, and metastatic hemangiopericytoma and malignant solitary fibrous tumor. Cancer, 117(21), 4939-4947. https://doi.org/10.1002/cncr.26098